Imagify™ (perflubutane polymer microspheres) injectable suspension for the assessment of coronary artery disease

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 3, 2007, Pages 413-421

  Senior, Roxy ^a,b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b MIDDLESEX UNIVERSITY   (United Kingdom)

Author keywords

Coronary heart disease; Diagnostic accuracy; Efficacy; Imagify ; Pharmakokinetics; Safety; Ultrasound contrast

Indexed keywords

AI 700; CARDIOSPHERE; CONSTA; ECHO CONTRAST MEDIUM; FS 069; GOSERELIN; IMAGIFY; LEUPRORELIN; MICROSPHERE; OCTREOTIDE; PERFLUORO COMPOUND; PERFLUOROBUTANE; PERFLUTREN; PLACEBO; POLYGLACTIN; RISPERIDONE; SONOVUE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUOROCARBON; POLYMER;

ANGIOCARDIOGRAPHY; ARTICLE; BLOOD OXYGEN TENSION; CLINICAL TRIAL; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; COUGHING; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DYSPNEA; FLUSHING; HEALTH CARE AVAILABILITY; HEART ARRHYTHMIA; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; IMAGE ANALYSIS; LEUKOCYTE COUNT; MEDICAL ASSESSMENT; MEDICAL RESEARCH; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; RADIATION EXPOSURE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; THORAX PAIN; VERTIGO; VOLUNTEER; CORONARY ARTERY ATHEROSCLEROSIS; ECHOGRAPHY; REVIEW;

CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; FLUOROCARBONS; HUMANS; MICROSPHERES; POLYMERS;

EID: 34249295930     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.3.413     Document Type: Article

References (27)

1. Kaul S. Myocardial contrast echocardiography in coronary artery disease: potential applications using venous injections of contrast. Am. J. Cardiol. 75(11), 61D-68D (1995).
2. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97(5), 473-483 (1998).
3. Monaghan M. Myocardial perfusion imaging during stress using contrast echocardiography. In: Contrast Echocardiograpby in Clinical Practice. Zamarano JL, Garcia-Fernandez MA (Eds). Springer, Milan, Italy, 175-190 (2007).
4. Moir S, Haluska BA, Jenkins C, Fathi R, Marwick TH. Incremental benefit of myocardial contrast to combined dipyridamole - exercise stress echocardiography for the assessment of coronary artery disease. Circulation 110(9), 1108-1113 (2004).
5. Wei K, Crouse L, Weiss J et al. Comparison of usefulness of dipyridamole stress myocardial contrast echocardiography to technetium-99m sestamibi single-photon emission computed tomography for detection of coronary artery disease (PB127 multicenter Phase 2 trial results). Am. J. Cardiol. 91(11), 1293-1298 (2003).
6. Senior R, Lepper W, Pasquet A et al. Myocardial perfusion assessment in patients with medium probability of coronary artery disease and no prior myocardial infarction: comparison of myocardial contrast echocardiography with 99mTc single-photon emission computed tomography. Am. Heart J. 147(6), 1100-1105 (2004).
7. Peltier M, Vancraeynest D, Pasquet A et al. Assessment of the physiologic significance of coronary disease with dipyridamole real-time myocardial contrast echocardiography. Comparison with technetium-99m sestamibi single-photon emission computed tomography and quantitative coronary angiography. J. Am. Coll. Cardiol. 43(2), 257-264 (2004).
8. Jeetley P, Hickman M, Kamp O et al. Myocardial contrast echocardiography for the detection of coronary artery stenosis: a prospective multicenter study in comparison with single-photon emission computed tomography. J. Am. Coll. Cardiol. 47(1), 141-145 (2006).
9. Dijkmans PA, Senior R, Becher H et al. Myocardial contrast echocardiography evolving as a clinically feasible technique for accurate, rapid, and safe assessment of myocardial perfusion: the evidence so far. J. Am. Coll. Cardiol. 48(11), 2168-2177 (2006).
10. Porter T, Kricsfeld D, Cheatham S, Li S. Effect of blood and microbubble oxygen and nitrogen content on perfluorocarbon-filled dextrose albumin microbubble size and efficacy: in vitro and in vivo studies. J. Am. Soc. Echocardiogr. 11 (5), 421-425 (1998).
11. Porter TR, Xie F, Li S, D'Sa A, Rafter P. Increased ultrasound contrast and decreased microbubble destruction rates with triggered ultrasound imaging. J. Am. Soc. Echocardiogr. 9(5), 599-605 (1996).
12. Porter TR, Li S, Kricsfeld D, Armbruster RW. Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging. J. Am. Coll. Cardiol. 29(4), 791-799 (1997).
13. Porter TR, Li S, Jiang L, Grayburn P, Deligonul U. Real-time visualization of myocardial perfusion and wall thickening in human beings with intravenous ultrasonographic contrast and accelerated intermittent harmonic imaging. J. Am. Soc. Echocardiogr. 12(4), 266-271 (1999).
14. Yao J, Takeuchi M, Teupe C et al. Evaluation of a new ultrasound contrast agent (AI-700) using two-dimensional and three-dimensional imaging during acute ischemia. J. Am. Soc. Echocardiogr. 15(7), 686-694 (2002).
15. Picard M, Pandian N, Morcerf F et al. The effects of AI-700 echo-contrast perfusion and/or wall motion imaging on detection of perfusion in patients with coronary artery disease [Abstract]. J. Am. Soc. Echocardiogr. 14, 460 (2001).
16. Shimoni S, Zoghbi WA, Xie F et al. Real-time assessment of myocardial perfusion and wall motion during bicycle and treadmill exercise echocardiography: comparison with single photon emission computed tomography. J. Am. Coll. Cardiol. 37(3), 741-747 (2001).
17. Church CC. The acoustical responses of AI-700 in vitro [Abstract]. J. Am. Soc. Echocardiogr. 13, 457 (2000).
18. Hamilos MI, Patrianakos AP. AI-700 (Acusphere). Curr. Opin. Investig. Drugs 6(9), 956-961 (2005).
19. Straub JA, Chickering DE, Church CC, Shah B, Hanlon T, Bernstein H. Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography. J. Control. Release 108(1), 21-32 (2005).
20. Acusphere Inc. Investigator's brochure: investigational product AI-700. Edition 5.0 (2006).
21. Straub JA, Chickering DE, Hartman TG, Gloff CA, Bernstein H. AI-700 pharmacokinetics, tissue distribution and exhaled elimination kinetics in rats. Int. J. Pharm. 328(1), 35-41 (2007).
22. Di Spirito M, Marier JF, Di Marco M, Ducharme MP, O'Dea CR, Walovitch RC. The pharmacokinetics of a perfluorocarbon gas - an echocardiographic contrast agent (AI-700) [Abstract]. AAPS PharmSci 5, (2003).
23. Walovitch RC, Kwan OL, Picard MH et al. Initial safety and myocardial perfusion imaging results with AI-700: a synthetic polymeric ultrasound contrast agent [Abstract]. J Am. Soc. Echocardiogr. 13, 457 (2000).
24. Weissman N, Grayburn P, Klein A. Comparison of myocardial contrast ECHO to 99mTC MIBI SPECT in patients with myocardial perfusion defects: a Phase 2 study of AI-700 [Abstract]. J. Am. Soc. Echocardiogr. 14, 461 (2001).
25. Grayburn PA, Zoghbi WA, Weissman NJ et al. Comparison of AI-700 echo and nuclear perfusion imaging to coronary angiography in patients with suspected coronary disease [Abstract]. J. Am. Soc. Echocardiogr. 17, 502 (2004).
26. van der Wouw PA, Brauns AC, Bailey SE, Powers JE, Wilde AA. Premature ventricular contractions during triggered imaging with ultrasound contrast. J. Am. Soc. Echocardiogr. 13(4), 288-294 (2000).
27. Yasumura S, Kubota I, Ikeda K, Tsuiki K, Yasui S. Using body surface mapping to detect vulnerability to ventricular arrhythmias in patients with coronary artery disease. J. Electrocardiol. 20(2), 114-120 (1987).